Cara Therapeutics Inc (CARA)’s Stock Is Buy After Today’s Big Increase

September 17, 2017 - By Ellis Scott

Investors sentiment decreased to 1.26 in Q4 2016. Its down 0.57, from 1.83 in 2016Q3. It fall, as 12 investors sold Cara Therapeutics Inc shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 12.12 million shares or 4.42% more from 11.60 million shares in 2016Q3 were reported.
Royal Retail Bank Of Canada owns 1,951 shares. Bank Of Ny Mellon holds 146,852 shares or 0% of its portfolio. Northern Corp has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Blackrock Advsr Limited Liability stated it has 12,483 shares or 0% of all its holdings. California State Teachers Retirement System invested in 0% or 43,254 shares. Nationwide Fund Advsrs holds 0% or 20,105 shares. Deutsche Natl Bank Ag holds 0% in Cara Therapeutics Inc (NASDAQ:CARA) or 24,499 shares. Blackrock Inv Limited Co accumulated 93,427 shares or 0% of the stock. Bnp Paribas Arbitrage invested 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Moreover, Cambridge Invest Research Advisors Inc has 0% invested in Cara Therapeutics Inc (NASDAQ:CARA). Millennium Mngmt Ltd invested in 16,372 shares or 0% of the stock. Blackrock Fund Advsrs holds 0% or 692,518 shares in its portfolio. Susquehanna International Gru Ltd Liability Partnership holds 0% in Cara Therapeutics Inc (NASDAQ:CARA) or 105,012 shares. Everpoint Asset Mngmt Ltd holds 0.09% or 500,000 shares in its portfolio. Wells Fargo & Comm Mn accumulated 0% or 23,951 shares.

Since March 31, 2017, it had 1 insider purchase, and 0 insider sales for $9.10 million activity. RHO Ventures VI LP bought $9.10 million worth of stock or 500,000 shares.

The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! The stock increased 3.47% or $0.46 on September 15, reaching $13.73. About 1.38 million shares traded or 24.32% up from the average. Cara Therapeutics Inc (NASDAQ:CARA) has risen 206.00% since September 17, 2016 and is uptrending. It has outperformed by 189.30% the S&P500.
The move comes after 7 months positive chart setup for the $447.34 million company. It was reported on Sep, 17 by We have $14.97 PT which if reached, will make NASDAQ:CARA worth $40.26 million more.

Analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to report $-0.37 EPS on November, 2.They anticipate $0.05 EPS change or 11.90 % from last quarter’s $-0.42 EPS. After having $-0.29 EPS previously, Cara Therapeutics Inc’s analysts see 27.59 % EPS growth.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Among 9 analysts covering Cara Therapeutics (NASDAQ:CARA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Cara Therapeutics had 20 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 4. On Friday, June 30 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating given on Thursday, July 13 by H.C. Wainwright. Canaccord Genuity maintained the shares of CARA in report on Friday, August 4 with “Buy” rating. The stock of Cara Therapeutics Inc (NASDAQ:CARA) has “Buy” rating given on Wednesday, June 21 by Needham. As per Friday, July 24, the company rating was maintained by Needham. As per Friday, June 30, the company rating was downgraded by Janney Capital. Piper Jaffray maintained the shares of CARA in report on Friday, August 4 with “Buy” rating. Cantor Fitzgerald initiated Cara Therapeutics Inc (NASDAQ:CARA) on Wednesday, November 4 with “Buy” rating. The company was maintained on Friday, June 30 by H.C. Wainwright.

More important recent Cara Therapeutics Inc (NASDAQ:CARA) news were published by: which released: “Big Investors Are Buying Cara Therapeutics Stock. Should You?” on August 31, 2017, also published article titled: “Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)”, published: “Here’s Why the Best Is Yet to Come for Cara Therapeutics, Inc.” on September 10, 2017. More interesting news about Cara Therapeutics Inc (NASDAQ:CARA) was released by: and their article: “Here’s Why Cara Therapeutics Rose 9.6% in August” with publication date: September 07, 2017.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $447.34 million. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It currently has negative earnings. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.